A detailed history of Melqart Asset Management (Uk) LTD transactions in Cytokinetics Inc stock. As of the latest transaction made, Melqart Asset Management (Uk) LTD holds 1,212,258 shares of CYTK stock, worth $59.2 Million. This represents 6.24% of its overall portfolio holdings.

Number of Shares
1,212,258
Previous 1,675,785 27.66%
Holding current value
$59.2 Million
Previous $90.8 Million 29.5%
% of portfolio
6.24%
Previous 7.69%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $23.7 Million - $27.9 Million
-463,527 Reduced 27.66%
1,212,258 $64 Million
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $33.1 Million - $52 Million
692,390 Added 70.41%
1,675,785 $90.8 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $62.7 Million - $106 Million
983,395 New
983,395 $68.9 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.6B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Melqart Asset Management (Uk) LTD Portfolio

Follow Melqart Asset Management (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.